This can be compared with, e.g. the ALK TKI lorlatinib, which leads to a robust initial inhibition of rate of tumour growth in ALK-driven NB models46,49, but is unable to deliver a complete response as was observed here with BAY 1895344. The gene discussed is ALK; the disease is neoplasm.